- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03355092
The vBlocT2D Study
vBloc Therapy for Obese Subjects With Type 2 Diabetes- A Randomized Controlled Clinical Trial
Overall aim: To demonstrate that weight loss through vBloc Therapy in combination with usual care will achieve better glycemic control for patients with obesity and type 2 diabetes than usual care alone.
Duration: Participants will be asked to participate in a 12 month study that involves a baseline visit and research follow-up visits at 3, 6, 9, and 12 months.
Sample Size: 60 participants will be enrolled in the study. Of these, 30 will be randomized to vBloc therapy and 30 will be randomized to usual care.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Harbor City, California, États-Unis, 90710
- Kaiser Permanente South Bay Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND
- Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND
- Age 18 years or older, AND
- Body mass index (BMI) 35-45 kg/m2 inclusive, AND
- Attempt and failed diet, exercise and behavioral modification program within past five years,
Exclusion Criteria:
- Use of GLP-1 receptor agonists for diabetes currently or within past 6 months
- Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators))
- Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body)
- Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation
- Previous bariatric or upper GI surgery
- Excessive alcohol intake
- Current smokers or smoking cessation in prior 3 months
- An underlying disease known to have important effects on glucose metabolism
- Active infections
- Anemia (Hemoglobin <11g/dl in women, <12 g/dl in men) or known coagulopathy
- Chronic kidney disease manifest as serum creatinine >2.0 mg/dl
- Diabetic retinopathy requiring photocoagulation therapy
- Symptomatic diabetic gastroparesis
- Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure
- Cirrhosis of the liver, portal hypertension, or esophageal varices
- Symptomatic esophageal reflux
Conditions or behaviors likely to affect the conduct of the vBloc Study
- Unable or unwilling to give informed consent
- Unable to adequately communicate with clinic staff
- Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study
- Likely to move away from participating clinic in next 2 years
- Current (or anticipated) pregnancy and lactation.
- Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study
- Weight loss >7% in past two months for any reason except postpartum weight loss.
- Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: vBloc Therapy + Usual Care for Type 2 Diabetes
|
The vBloc device will be placed using a laparoscopic procedure.
The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. .
Pre-operative testing will be conducted per surgeon's evaluation.
Participants will receive weight management education according to the vBloc Therapy protocol.
|
|
Aucune intervention: Usual Care for Type 2 Diabetes
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Mean reduction in HbA1c
Délai: at 12 months after baseline
|
at 12 months after baseline
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Anny Xiang, PhD, Kaiser Permanente
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KPSC IRB 11343 (Autre identifiant: Kaiser Permanente Southern California IRB)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .